Androgen Deprivation for Prostate Cancer

Posted by Graham McMahon • July 15th, 2011

In a new study by Jones et al., Radiotherapy and Short-Term Androgen Deprivation for Localized Prostate Cancer, a course of androgen-deprivation therapy before and during radiotherapy prolonged 10-year survival by about 7% among men with intermediate-risk prostate cancer. The risk of erectile dysfunction with the addition of hormone therapy was also about 7% higher.

In the 1990s, reversible androgen suppression with the use of luteinizing hormone-releasing hormone analogues and oral antiandrogen agents was shown to induce apoptotic regression in androgen-responsive cancers, potentially improving the prospects of local control and the duration of survival free of metastatic disease.

Clinical Pearls

How can short-term androgen deprivation be achieved?

In this study, patients assigned to short-term androgen-deprivation therapy (ADT) received flutamide at a dose of 250 mg orally three times a day and either monthly subcutaneous goserelin at a dose of 3.6 mg or intramuscular leuprolide at a dose of 7.5 mg for 4 months.

How more effective was ADT with radiotherapy as compared to radiotherapy alone for patients with localized  prostate cancer in this study?

According to the results of this study, the 10-year rate of overall survival was 62% among patients receiving  radiotherapy plus short-term ADT (the combined-therapy group) versus 57% among patients receiving radiotherapy alone (hazard ratio for death with radiotherapy alone, 1.17; P=0.03). The addition of short-term ADT was associated with a decrease in the 10-year disease-specific mortality from 8% to 4% (hazard ratio for radiotherapy alone, 1.87; P=0.001).

Morning Report Questions

Q: Which group of patients benefited the most from ADT in this study?

A: The addition of short-term ADT to radiotherapy conferred the greatest clinical benefit in the intermediate-risk  subgroup, with an increase in the 10-year rate of overall survival from 54 to 61% and a reduction in the 10-year  disease-specific mortality from 10 to 3%.

Q: What are adverse effects of ADT?

A: In prospective studies, short-term ADT caused measurable muscle loss, fat accumulation, decreased insulin  sensitivity, and increased cholesterol and triglyceride levels.

One Response to “Androgen Deprivation for Prostate Cancer”

  1. Sana says:

    Could you please tell me how you are coming up with the percentiles for the question ” How more effective was ADT with radiotherapy as compared to radiotherapy alone for patients with localized prostate cancer in this study?” thank you.

Leave a Reply

Please note: Comment moderation is enabled and may delay your comment. There is no need to resubmit your comment.

Submitting a comment indicates you have read and agreed to the Terms and Conditions.